Cumberland Pharmaceuticals Inc.
| NASDAQ: CPIX | Healthcare / Drug Manufacturers / USA |
| 1.65 | -0.0600 | -3.51% | Vol 4.93K | 1Y Perf -28.70% |
| Nov 29th, 2023 16:00 DELAYED |
| BID | 1.57 | ASK | 2.50 | ||
| Open | 1.67 | Previous Close | 1.71 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 8.50 | Analyst Rating | — 0.00 | |
| Potential % | 415.15 | Finscreener Ranking | ★★★★★ 58.67 | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★★+ 52.49 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★+ 42.10 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 14.86 | Earnings Rating | Buy | |
| Market Cap | 23.52M | Earnings Date | 7th Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.15 | |
| Beta | 0.22 |
Today's Price Range 1.651.75 | 52W Range 1.432.91 | 5 Year PE Ratio Range -83.90-14.90 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -3.51% | ||
| 1 Month | -15.82% | ||
| 3 Months | -1.79% | ||
| 6 Months | 3.77% | ||
| 1 Year | -28.70% | ||
| 3 Years | -44.26% | ||
| 5 Years | -73.68% | ||
| 10 Years | -66.95% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -3.76 | |||
ROE last 12 Months | -17.79 | |||
ROA (5Y Avg) | -2.19 | |||
ROA last 12 Months | -8.46 | |||
ROC (5Y Avg) | -7.20 | |||
ROC last 12 Months | -11.27 | |||
Return on invested Capital Q | -0.57 | |||
Return on invested Capital Y | -6.28 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 3.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -5.20 | ||||
| 0.91 | ||||
| 1.10 | ||||
| 5.30 | ||||
| -3.90 | ||||
| 0.46 | ||||
| 4.52 | ||||
| 2.68 | ||||
| 33.54M | ||||
| Forward PE | 86.20 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.40 | ||||
| 1.90 | ||||
| 0.31 | ||||
| 0.46 | ||||
| -16.40 | ||||
| Leverage Ratio | 2.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 75.70 | ||||
| -17.30 | ||||
| -3.00 | ||||
| -24.80 | ||||
| -9.70 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 32.89M | ||||
| 2.27 | ||||
| -7.60 | ||||
| -0.71 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | 0.15 | - |
| Q01 2023 | - | 0.10 | - |
| Q03 2022 | - | 0.09 | - |
| Q02 2022 | - | -0.01 | - |
| Q01 2022 | - | 0.02 | - |
| Q04 2021 | - | -0.14 | - |
| Q03 2021 | - | -0.03 | - |
| Q02 2021 | -0.09 | -0.01 | 88.89 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2021 QR | -0.03 | 0.00 | - |
| 12/2021 QR | 0.06 | 0.00 | - |
| 12/2021 FY | 0.00 | - | - |
| 12/2022 FY | 0.02 | 0.00 | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 4.93K |
| Shares Outstanding | 14.26K |
| Shares Float | 8.26M |
| Trades Count | 41 |
| Dollar Volume | 8.38K |
| Avg. Volume | 12.30K |
| Avg. Weekly Volume | 6.27K |
| Avg. Monthly Volume | 12.74K |
| Avg. Quarterly Volume | 17.89K |
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) stock closed at 1.65 per share at the end of the most recent trading day (a -3.51% change compared to the prior day closing price) with a volume of 4.93K shares and market capitalization of 23.52M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 94 people. Cumberland Pharmaceuticals Inc. CEO is A. J. Kazimi.
The one-year performance of Cumberland Pharmaceuticals Inc. stock is -28.7%, while year-to-date (YTD) performance is -26.67%. CPIX stock has a five-year performance of -73.68%. Its 52-week range is between 1.43 and 2.91, which gives CPIX stock a 52-week price range ratio of 14.86%
Cumberland Pharmaceuticals Inc. currently has a PE ratio of -5.20, a price-to-book (PB) ratio of 0.91, a price-to-sale (PS) ratio of 1.10, a price to cashflow ratio of 5.30, a PEG ratio of -, a ROA of -8.46%, a ROC of -11.27% and a ROE of -17.79%. The company’s profit margin is -9.70%, its EBITDA margin is -3.00%, and its revenue ttm is $32.89 Million , which makes it $2.27 revenue per share.
Of the last four earnings reports from Cumberland Pharmaceuticals Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cumberland Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Cumberland Pharmaceuticals Inc. is — (0), with a target price of $8.5, which is +415.15% compared to the current price. The earnings rating for Cumberland Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cumberland Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cumberland Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.94, ATR14 : 0.16, CCI20 : -64.44, Chaikin Money Flow : -0.26, MACD : -0.07, Money Flow Index : 35.95, ROC : -1.20, RSI : 41.48, STOCH (14,3) : 10.00, STOCH RSI : 0.00, UO : 30.32, Williams %R : -90.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cumberland Pharmaceuticals Inc. in the last 12-months were:
Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It focuses on the acquisition, development, and commercialization of branded prescription products. The company provides prescription products to hospital acute care and gastroenterology to address unmet or poorly met medical needs. Its product brands include Acetadote, Caldolor, Kristalose, Omeclamox- Pak, Vaprisol and Ethyol.
CEO: A. J. Kazimi
Telephone: +1 615 255-0068
Address: 2525 West End Avenue, Nashville 37203, TN, US
Number of employees: 94
